Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-10T22:46:03.010Z Has data issue: false hasContentIssue false

Chapter 28 - Botulinum Toxin in the Treatment for Ischemic Digits and Chronic Pain

Published online by Cambridge University Press:  02 November 2023

Daniel Truong
Affiliation:
University of California, Riverside
Dirk Dressler
Affiliation:
Hannover Medical School
Mark Hallett
Affiliation:
National Institutes of Health (NIH)
Christopher Zachary
Affiliation:
University of California, Irvine
Mayank Pathak
Affiliation:
Truong Neuroscience Institute
Get access

Summary

Raynaud’s phenomenon is a vasospastic disorder with a reported prevalence of between 3% and 5% of the general population, is nine times more common in females and typically occurs between the ages of 15–40 years. It may be primary or occur in the setting of connective tissue disorders. Exaggerated vasoconstriction of the digital arteries in response to certain environmental triggers, typically cold temperatures, leads to pale, cold, numb and sometimes painful digits. In extreme cases, digital artery vasospasm leads to diminished blood supply to the fingertips, which causes pain, disuse and exposure of the distal phalanx, and may necessitate amputation.

Injection of botulinum neurotoxin (BoNT) into the hand, typically at the base of the fingers, produces increased blood flow, oxygenation saturation, pain reduction and promotion of ulcer healing, with prolonged benefit over several months. This chapter details the use of BoNT for ischemic digits caused by Raynaud’s phenomenon, including injection technique, dosing and quantification of perfusion and oxygenation using laser Doppler.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bello, R, Cooney, C, Melamed, E et al. (2017). the therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud’s phenomenon: a randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol, 69, 1661–9.CrossRefGoogle ScholarPubMed
de Trafford, J, Lafferty, K, Potter, C, Roberts, V, Cotton, L (1988). An epidemiological survey of Raynaud’s phenomenon. Eur J Vasc Surg, 2, 167–70.CrossRefGoogle ScholarPubMed
Fregene, A, Ditmars, D, Siddiqui, A (2009). Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud’s phenomenon. J. Hand Surg Am, 34, 446–52.CrossRefGoogle ScholarPubMed
Goldberg, S, Akoon, A, Kirchner, H, Deegan, J (2021). The effects of botulinum toxin A on pain in ischemic vasospasm. J Hand Surg Am, 46, 513e1–12.Google Scholar
Maundrell, A, Proudman, S (2015). Epidemiology of Raynaud’s Phenomenon. In Wigley, FM, Herrick, AL, Flavahan, NA (eds.) Raynaud’s Phenomenon: A Guide to Pathogenesis and Treatment. New York: Springer, pp. 2135.CrossRefGoogle Scholar
Medina, S, Gómez-Zubiaur, A, Valdeolivas-Casillas, N et al. (2018). Botulinum toxin type A in the treatment of Raynaud’s phenomenon: a three-year follow-up study. Eur J Rheumatol, 5, 224–9.CrossRefGoogle ScholarPubMed
Neumeister, M. (2010). Botulinum toxin type A in the treatment of Raynaud’s phenomenon. J Hand Surg Am, 35(12), 2086–92.CrossRefGoogle ScholarPubMed
Neumeister, M, Chambers, C, Herron, M et al. (2009). Botox therapy for ischemic digits. Plast Reconstr Surg, 124 , 191201.CrossRefGoogle ScholarPubMed
Sycha, T, Graninger, M, Auff, E, Schnider, P (2004). Botulinum toxin in the treatment of Raynaud’s phenomenon: a pilot study. Eur J Clin Invest, 34, 312–13.Google Scholar
Van Beek, A, Lim, P, Gear, A, Pritzker, M (2007). Management of vasospastic disorders with botulinum toxin A. Plast Reconstr Surg, 119, 217–-26Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×